Head-to-head · WeighScore
NextMeds vs TD Tele-Doc Weight Loss
The verdict
NextMeds takes it — 66.3/100 to 61.8/100.
NextMeds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NextMeds is a cash-pay telehealth platform offering compounded semaglutide and compounded tirzepatide on a flat monthly membership — one price bundling the medication (if prescribed), telehealth visits, a…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | NextMeds | TD Tele-Doc Weight Loss |
|---|---|---|
| WeighScore | 66.3/100 | 61.8/100 |
| Grade | C | C |
| Scorecard rank | #191 | #286 |
| Semaglutide | $129/mo (plus a separate fee, compounded) | Not disclosed |
| Tirzepatide | $179/mo (plus a separate fee, compounded) | Not disclosed |
| Coverage | All 50 states | 2 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #191 · C
Strengths
- Flat monthly membership bundles the medication, telehealth visits, a 1:1 care coach and a licensed registered dietitian — one price, no hidden fees
- Same price every dose, no auto-renewal, cancel anytime; free shipping and no insurance needed (FSA eligible)
- Names a compounding pharmacy partner (Foothills Pharmacy) and states it services all 50 states
- Free, no-obligation online assessment before you pay anything
Where it loses points
- Shows a LegitScript 'approval' but links only a generic directory search, not a verifiable seal — we couldn't independently confirm it
- Promo-driven pricing with a countdown timer and 'price increases' urgency; the standing membership is $129 (sema) / $179 (tirz)
- A technology platform that coordinates care, not the medical provider; individual clinicians and a medical director aren't named on the site
- Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
- Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name
Graded #286 · C
Strengths
- Brand Wegovy/Zepbound AND compounded sema available; prescribing based on medical history and coverage
- 100% virtual — weekly appointments with board-certified MDs from home; no travel required
- Remote Patient Monitoring Starter Box: biometric scale + blood pressure cuff sync to care team in real time
- In-network with most commercial insurance plans; may cover visits and monitoring equipment
- Physician-led by Dr. Peter Wilbanks MD (30-yr OB/GYN, VCU) and Dr. Michael Perini MD (ABIM board-certified)
Where it loses points
- No public cash pricing; cost entirely depends on insurance coverage — not viable for uninsured patients
- Telehealth available only in Virginia and Maryland; no national reach confirmed
- No Medicare or Medicaid accepted; limited to commercial insurance plans only
- No LegitScript certification found; compounded availability and specific pricing undisclosed on site
- Tirzepatide (Zepbound/Mounjaro) availability less prominent in MD pages; semaglutide is primary focus
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.